Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy

National Taiwan University Hospital60 enrolled

Overview

The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Head and Neck Cancers Patients

Interventions

Serum levels of immunologic profilesDIAGNOSTIC_TEST

Serum levels of immunologic profiles before and after chemoradiotherapy

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department. Exclusion Criteria: * Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Disease progression

Tumor local recurrence or distant metastasis

Time frame: Three years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.